ERBB2 and breast carcinoma: Strengths of this study include the complete and accurate prospective ascertainment of HER2-defined breast cancer development based on routine linkage of the cohort to the statewide cancer registry, linkage to hospital discharge summary data to confirm any previous myocardial infarction, and a median of 7 years of follow up.